Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study - Innovaderm Research

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Test

Post navigation

Prospective Study of Pathogenesis of Atrophic Acne Scars and Role of Macular Erythema

Persistence of interleukin (IL)-17A⁺ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Dermatology Clinic
3530 Saint-Laurent boulevard
Suite 400
Montreal, QC, H2X 2V1, Canada

© Innovaderm 2025. All rights reserved.